Generics

  • Hi-Tech Pharmacal posts $3 million loss

    AMITYVILLE, N.Y. Hi-Tech Pharmacal had $40.4 million in sales during its fiscal first quarter ended July 31, the generic drug maker said Thursday. The numbers amounted to a decrease of $3 million from the same period in 2009.

     

  • Greenstone, Eisai to launch authorized generic of Aricept

    PEAPACK, N.J. The generics division of Pfizer will sell an authorized generic version of a drug used to treat dementia.

     

    Greenstone said Wednesday that it had agreed with Eisai to launch donepezil hydrochloride tablets, an authorized generic of Aricept. The drug is used to treat dementia related to Alzheimer’s disease. Eisai makes the drug under a partnership with Pfizer.

     

     

  • Watson gets FDA approval for generic Yasmin

    MORRISTOWN, N.J. The Food and Drug Administration has approved a generic oral contraceptive made by Watson Pharmaceuticals, the drug maker said Tuesday.

     

    Watson announced the FDA’s approval of Zarah (drospirenone and ethinyl estradiol tablets) in the 3 mg/0.03 mg strength. The drug is a generic version of Bayer’s Yasmin.

     

     

  • Greenstone to launch Authorized Generics Alliance

    PEAPACK, N.J. The generics subsidiary of Pfizer is launching a new business focused on authorized generics.

     

    Greenstone announced Tuesday the launch of the Authorized Generics Alliance, which it said would combine its business model and 17 years of experience in the generics market with the expertise of other drug makers to market authorized generics in the United States under the Greenstone label.

     

     

  • Watson confirms patent challenge for generic Combigan

    MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a version of a drug used to treat eye diseases, Watson said Tuesday.

  • Mylan closes Bioniche acquisition

    PITTSBURGH Generic drug maker Mylan has managed to snag Bioniche Pharma Holdings sooner than expected, Mylan said Tuesday. Mylan had announced its plans to buy Bioniche for $550 million in July.

     

  • Actavis' generic Strattera gets OK from FDA

    MORRISTOWN, N.J. The Food and Drug Administration has approved a generic drug made by Actavis for treating attention deficit hyperactivity disorder, Actavis said Wednesday.

     

    The FDA approved the drug maker’s atomoxetine hydrochloride capsules in the 10-mg, 18-mg, 25-mg, 40-mg, 60-mg, 80-mg and 100-mg strengths. The drug is a generic version of Eli Lilly’s Strattera, which had $532 million in sales during the 12-month period ended in June, according to IMS Health.

     

     

  • Teva markets AcuDial generic

    NORTH WALES, Pa. Teva Pharmaceuticals has launched a generic treatment for epileptic seizures.

     

    The world’s largest generic drug maker announced Wednesday the launch of diazepam rectal gel, a generic version of Valeant Pharmaceuticals’ Diastat AcuDial. The drug is administered via rectal syringe and is available in 2.5-mg, 10-mg and 20-mg strengths.

     

     

  • FDA approves Sun's generic Strattera

    MUMBAI, India A generic drug maker has received regulatory approval for its version of an attention deficit hyperactivity disorder treatment.

    Sun Pharmaceutical Industries' subsidiary has received approval to market its generic version of Strattera (atomoxetine hydrochloride capsules), an ADHD drug for children ages 6 years and older, as well as teens and adults. Strattera is made and marketed by Eli Lilly.

    Annual sales of branded and generic atomoxetine hydrochloride capsules are estimated to be more than $530 million.

  • Sigmapharm files ANDA for generic Hepsera

    FOSTER CITY, Calif. A generic drug maker has filed an abbreviated new drug application for its version of a Gilead Sciences drug.

    FOSTER CITY, Calif. A generic drug maker has filed an abbreviated new drug application for its version of a Gilead Sciences drug.

X
This ad will auto-close in 10 seconds